• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth & Martha Stewart CBD Brand Being Sued By Oregon Edibles Producer For Copyright Infringement

    9/16/22 10:17:32 AM ET
    $CGC
    $SQBG
    Medicinal Chemicals and Botanical Products
    Health Care
    Apparel
    Consumer Non-Durables
    Get the next $CGC alert in real time by email

    Canopy Growth Corp. (TSX:WEED) (NASDAQ:CGC) and Martha Stewart Living Omnimedia - based in New York and owned by Marquee Brands - are being sued by Northwest Natural Goods for a copyright and trade dress infringement, reported Marijuana Business Daily.

    Filed by Perkins Coie on behalf of Northwest Natural Goods earlier this month, the complaint accused the defendants of launching a line of CBD products with packaging nearly identical to Wyld's.

    The Complaint

    The complaint from the Portland-based cannabis edibles company behind the brand 'Wyld' alleges that Northwest Natural Goods and Canopy Rivers, a former strategic investment subsidiary of the Canadian cannabis giant, collaborated on the Wyld CBD line of products for several months in 2019, as first reported by Law360.

    During that time Northwest Natural Goods allegedly provided Canopy Rivers with a Wyld CBD business plan, which included "trade dress" and copyrighted materials for the brand's blackberry, lemon and raspberry CBD gummies.

    "Prior to distributing the Martha Stewart CBD products, defendants knew of Wyld's trade dress and, on information and belief, intentionally copied that trade dress to trade off of Wyld's goodwill and reputation," the complaint said.

    Stewart took an advisory role at Canopy in February 2019 as part of the collaboration between the cannabis company and Sequential Brands Group, Inc. (NASDAQ:SQBG).

    In September 2020, the partnership resulted in a new line of hemp-derived wellness supplements.

    In the following years, the collaboration between Canopy and the "Domestic Diva" yielded a myriad of new products, including Martha Stewart CBD Wellness Gummies Sampler, a new line of CBD for Pet products and the latest limited-edition wellness gummy, Pumpkin Spice, to name a few.

    Meanwhile, the complaint also noted that in some retail locations, Wyld products and Martha Stewart CBD gummies are placed side by side on shelves, causing confusion among consumers.

    Northwest Natural Goods is now pursuing compensation, "compensatory damages in an amount to be determined at trial, attorneys' fees, costs and disbursements."

    Cointreau's Accusations

    In a related issue earlier this year, Remy Cointreau (OTC:REMYY) put an end to a lawsuit the French alcohol maker filed against Canopy, accusing it of alleged trademark infringement over its CBD-infused sparkling water brand dubbed Quatreau, according to a New York court filing.

    Initially, Cointreau claimed that Canopy used Quatreau "in order to unfairly capitalize on the goodwill and reputation of the Cointreau mark," and that "(The) defendants' wilful actions will not only confuse consumers as to their affiliation with plaintiffs and the Cointreau brand but will blur the exclusive association plaintiff enjoys between Cointreau and a single source of orange liqueurs."

    CGC Price Action

    Canopy's shares traded 4.9419% lower at $3.29 per share at the time of writing on Friday morning.

    Photo: Benzinga Edit, Source: Shutterstock

    Get the next $CGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGC
    $SQBG

    CompanyDatePrice TargetRatingAnalyst
    Canopy Growth Corporation
    $CGC
    3/27/2026Buy
    Canaccord Genuity
    Canopy Growth Corporation
    $CGC
    11/10/2025Sell → Hold
    The Benchmark Company
    Canopy Growth Corporation
    $CGC
    4/4/2023Underperform → Mkt Perform
    Bernstein
    Canopy Growth Corporation
    $CGC
    11/2/2022$1.50Underperform
    Bernstein
    Canopy Growth Corporation
    $CGC
    10/26/2022Sell → Hold
    Canaccord Genuity
    Canopy Growth Corporation
    $CGC
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    Canopy Growth Corporation
    $CGC
    3/22/2022Equal Weight → Underweight
    Barclays
    Canopy Growth Corporation
    $CGC
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    More analyst ratings

    $CGC
    $SQBG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy Growth Unveils New Brand 'Deelish': High THC, Everyday Price

    27%-33% THC flower, and 26%-32% THC pre-rolls across rotating genetics Now available at select stores across Ontario and Alberta Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced Deelish ("DEE-LISH"), a new cannabis brand built for the everyday consumer with an everyday price. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331523789/en/High THC, Everyday Price. Deelish is Canopy Growth's newest brand, delivering high THC with flower testing at 27%-33% THC and pre-rolls at 26%-32% THC. Deelish enters the market built to deliver high THC with flower testing at 27%-33% THC a

    3/31/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth's Apollo Cannabis Clinics Named Best Medical Cannabis Clinic

    Voted best by Toronto Star Readers' Choice Awards Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced that its Apollo Cannabis Clinics ("Apollo") has been named Best Medical Cannabis Clinic in the 2025 Toronto Star's Readers' Choice Awards, a public vote that reflects the trust patients place in Apollo's care. Apollo represents the Company's commitment to raising the standard of medical cannabis and making quality treatment accessible to every Canadian. "This recognition comes directly from the people we care for, and that makes it especially meaningful," said Luc Mongeau, Chief Executive Officer of Canopy Growth. "Everything Apollo doe

    3/30/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $SQBG
    SEC Filings

    View All

    Canopy Growth Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Canopy Growth Corp (0001737927) (Filer)

    3/16/26 7:59:07 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form EFFECT filed by Canopy Growth Corporation

    EFFECT - Canopy Growth Corp (0001737927) (Filer)

    2/17/26 12:15:34 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B3 filed by Canopy Growth Corporation

    424B3 - Canopy Growth Corp (0001737927) (Filer)

    2/13/26 4:08:07 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $SQBG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mongeau Luc bought $49,994 worth of shares (27,469 units at $1.82), increasing direct ownership by 3% to 812,368 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    9/23/25 4:15:11 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $SQBG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Yanofsky Theresa

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:16:22 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Atkins M Shan

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:16:02 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Bayern Joseph

    4 - Canopy Growth Corp (0001737927) (Issuer)

    4/2/26 4:15:39 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $SQBG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by The Benchmark Company

    The Benchmark Company upgraded Canopy Growth from Sell to Hold

    11/10/25 8:33:16 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by Bernstein

    Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

    4/4/23 9:09:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $SQBG
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Completes Acquisition of MTL Cannabis Creating Canada's Leading Medical Cannabis Business By Revenue

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Strengthens Canopy Growth's core Canadian platform, providing additional high-quality flower to support international growth Expected run-rate synergies of approximately $10 million within 18 months Canopy Growth's leadership team and operational depth strengthened through addition of MTL management team members Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) and MTL Cannab

    3/16/26 7:41:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth to Acquire MTL Cannabis; Transaction Expected to Create Canada's Leading Medical Cannabis Business and Enhance Capacity to Serve Growing International Demand

    This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024 All financial amounts in this press release are expressed in Canadian dollars. Highly accretive business combination expected to generate significant run-rate synergies of approximately $10 million within 18 months Strengthens Canopy Growth's presence in Québec with an opportunity to expand national distribution of MTL's high-quality, budtender-recommended product portfolio2 MTL's core management team is expected to join Canopy Growth to drive cultivation excellence and enhance the Company's p

    12/15/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $SQBG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    4/19/24 5:00:49 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    11/3/23 4:30:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    7/20/23 4:35:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    $SQBG
    Financials

    Live finance-specific insights

    View All

    Canopy Growth to Report Third Quarter Fiscal 2026 Financial Results on February 6, 2026

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2026 ended December 31, 2025 before financial markets open on February 6, 2026. Following the release of its third quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on February 6, 2026 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=45C34153-5530-4D6A-A742-BC34AD2534FA Replay Information A replay will be accessible by webcast until 11:59 PM ET on May 7, 2026 at:

    1/23/26 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Second Quarter Fiscal 2026 Financial Results; Company Continues to Strengthen Financial Performance with Improving Adjusted EBITDA, Disciplined Cost Management, and a Stronger Balance Sheet

    Canada adult-use revenue up 30% in Q2 FY2026 and 37% year-to-date, reflecting the benefits of our focused commercial strategy and more disciplined execution Canada medical revenue up 17% in Q2 FY2026 and 15% year-to-date, marking another standout quarter for growth $298MM cash and cash equivalents, which exceeds debt balances by $70MM at September 30, 2025; as a result, conditions that previously raised substantial doubt concerning the Company's ability to continue as a going concern have been resolved Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the second quarter ended September 30, 2025 ("Q2 FY2026"). Al

    11/7/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth to Report Second Quarter Fiscal 2026 Financial Results on November 7, 2025

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2026 ended September 30, 2025 before financial markets open on November 7, 2025. Following the release of its second quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO on November 7, 2025 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=EEDC9A65-53FA-40BD-9644-D3ABDCF91E72 Replay Information A replay will be accessible by webcast until 11:59 PM ET on February 5, 2026

    10/24/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care